PMID- 25096201
OWN - NLM
STAT- MEDLINE
DCOM- 20160317
LR  - 20211021
IS  - 1573-7365 (Electronic)
IS  - 0885-7490 (Linking)
VI  - 30
IP  - 1
DP  - 2015 Feb
TI  - Attenuation of ecstasy-induced neurotoxicity by N-acetylcysteine.
PG  - 171-81
LID - 10.1007/s11011-014-9598-0 [doi]
AB  - Exposure to 3, 4-methylenedioxymethamphetamine (MDMA) can lead to spatial memory 
      impairments and hippocampal cell death. Numerous evidence indicates that the 
      antioxidant N-acetylcysteine (NAC) exerts protective effects in the brain. The 
      present study evaluates the effects of NAC on MDMA-induced neurotoxicity. 
      METHODS: We intraperitoneally injected 28 adult male Sprague-Dawley rats (200-250 
      g) with either 0, 10 mg/kg of MDMA, or 10 mg/kg of MDMA plus 100 mg/kg of NAC. 
      Spatial memory was assessed with a Morris Water Maze (MWM). At the end of the 
      study, rats' brains were removed to study the structure and ultrastructure of 
      CA1, and measure Bcl-2 and Bax expressions in the hippocampus. In the MWM, NAC 
      treatment significantly attenuated the MDMA-induced increase in distance traveled 
      (p < 0.05) and escape latency (p < 0.001). The decreased time spent in the target 
      quadrant in MDMA-treated animals was attenuated by NAC (p < 0.01). NAC 
      significantly protected against MDMA-induced apoptosis and the up- and 
      down-regulation of Bax and Bcl-2, respectively. These data have suggested that 
      NAC could protect against behavioral changes and apoptosis in the hippocampus 
      following administration of MDMA. NAC might be useful for the treatment of 
      neurotoxicity in MDMA users.
FAU - Soleimani Asl, Sara
AU  - Soleimani Asl S
AD  - Research Center for Behavioral Disorders and Substance Abuse, Hamadan University 
      of Medical Sciences, Hamadan, Iran.
FAU - Saifi, Bita
AU  - Saifi B
FAU - Sakhaie, Abolhasan
AU  - Sakhaie A
FAU - Zargooshnia, Somayeh
AU  - Zargooshnia S
FAU - Mehdizadeh, Mehdi
AU  - Mehdizadeh M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140806
PL  - United States
TA  - Metab Brain Dis
JT  - Metabolic brain disease
JID - 8610370
RN  - 0 (Antioxidants)
RN  - 0 (Bax protein, rat)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-2-Associated X Protein)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*therapeutic use
MH  - Animals
MH  - Antioxidants/*therapeutic use
MH  - Apoptosis/drug effects
MH  - CA1 Region, Hippocampal/drug effects/pathology
MH  - Drug Evaluation, Preclinical
MH  - Learning Disabilities/chemically induced/*prevention & control
MH  - Male
MH  - Maze Learning/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Nerve Tissue Proteins/biosynthesis/genetics
MH  - Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spatial Memory/drug effects
MH  - bcl-2-Associated X Protein/biosynthesis/genetics
EDAT- 2014/08/07 06:00
MHDA- 2016/03/18 06:00
CRDT- 2014/08/07 06:00
PHST- 2014/04/29 00:00 [received]
PHST- 2014/07/24 00:00 [accepted]
PHST- 2014/08/07 06:00 [entrez]
PHST- 2014/08/07 06:00 [pubmed]
PHST- 2016/03/18 06:00 [medline]
AID - 10.1007/s11011-014-9598-0 [doi]
PST - ppublish
SO  - Metab Brain Dis. 2015 Feb;30(1):171-81. doi: 10.1007/s11011-014-9598-0. Epub 2014 
      Aug 6.